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Abstract
Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) are 
rare, inherited cholestatic liver disorders that manifest in infants and children and 
are associated with impaired bile flow (ie cholestasis), pruritus and potentially fatal 
liver disease. There are no effective or approved pharmacologic treatments for these 
diseases (standard medical treatments are supportive only), and new, noninvasive 
options would be valuable. Typically, bile acids undergo biliary secretion and intesti-
nal reabsorption (ie enterohepatic circulation). However, in these diseases, disrupted 
secretion of bile acids leads to their accumulation in the liver, which is thought to 
underlie pruritus and liver-damaging inflammation. One approach to reducing patho-
logic bile acid accumulation in the body is surgical biliary diversion, which interrupts 
the enterohepatic circulation (eg by diverting bile acids to an external stoma). These 
procedures can normalize serum bile acids, reduce pruritus and liver injury and im-
prove quality of life. A novel, nonsurgical approach to interrupting the enterohepatic 
circulation is inhibition of the ileal bile acid transporter (IBAT), a key molecule in the 
enterohepatic circulation that reabsorbs bile acids from the intestine. IBAT inhibition 
has been shown to reduce serum bile acids and pruritus in trials of paediatric chole-
static liver diseases. This review explores the rationale of inhibition of the IBAT as 
a therapeutic target, describes IBAT inhibitors in development and summarizes the 
current data on interrupting the enterohepatic circulation as treatment for choles-
tatic liver diseases including ALGS and PFIC.
K E Y W O R D S
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1  | INTRODUC TION
Adequate enterohepatic circulation is crucial for homeostatic 
maintenance of the bile acid pool in the body. This process starts 
with bile acid synthesis in hepatocytes and their subsequent bil-
iary secretion, primarily mediated by the bile salt export pump 
(BSEP) at the apical (canalicular) membrane. Bile salts then move 
through bile ducts as constituents of bile to the gallbladder for 
storage and, later, for release into the small intestine to aid in 
lipid digestion and absorption. Per cycle, up to 95% of bile acids 
are reabsorbed from the terminal ileal lumen by the ileal bile acid 
transporter (IBAT; also known as the apical sodium-dependent bile 
acid transporter) for return to the liver through the portal veins 
(Figure 1A).1 Bile acid export from hepatocytes may occur at the 
basolateral membrane, which directs bile acids into systemic cir-
culation. Under physiologic conditions, this export pathway is 
minimal; however, this may be enhanced in certain situations as 
a hepatoprotective mechanism, such as during cholestasis.2,3 Bile 
acids that are not recovered from the intestine are lost in faeces 
(~5%) and, under steady-state conditions, are replaced by hepatic 
de novo synthesis.
The bile acid pool size is regulated by feedback loops: the nu-
clear sensor farnesoid X receptor (FXR) responds to bile acid con-
centrations at various points along the enterohepatic circulation 
by signalling to repress the synthesis of additional bile acids. For 
example, after bile acid reuptake from the intestinal lumen at the 
level of the terminal ileum, the bile acids activate FXR and thereby 
FXR-responsive genes like fibroblast growth factor 19 (FGF19); once 
expressed, FGF19 protein is secreted and relays information from 
enterocytes to the liver, such that enzymes involved in the synthesis 
of bile acids (eg cholesterol 7 alpha-hydroxylase) are subsequently 
repressed. Bile acid synthesis is commonly quantified by the serum 
levels of the intermediate synthesis product C4 (7α-hydroxy-4-cho-
lesten-3-one), which tends to negatively correlate with FGF19 lev-
els (ie bile acid accumulation drives FGF19 formation, resulting in 
lower C4 levels [and bile acid synthesis; Figure  1A]1; the converse 
is also true: diminished intestinal FXR activation by bile acids de-
creases FGF19 production, leading to enhanced bile acid synthesis 
and higher C4 levels).4,5
Cholestasis is defined as the impaired formation or flow of bile 
in the hepatobiliary system and may be intrahepatic (involving he-
patocytes, bile canaliculi or intrahepatic bile ducts) or extrahepatic 
(involving the bile ducts outside the liver or the gallbladder).6-8 In 
cholestasis, which can present with features of jaundice or pruri-
tus, the accumulation of bile acids may damage liver cells such that 
fibrotic and inflammatory pathways are activated that lead to liver 
injury.1,2,6 Common cholestatic liver diseases include Alagille syn-
drome (ALGS), progressive familial intrahepatic cholestasis (PFIC) 
and biliary atresia in children and primary biliary cholangitis (PBC) or 
primary sclerosing cholangitis (PSC) in adults.
This review focuses on ALGS and PFIC, which are inherited and 
severe intrahepatic cholestatic liver diseases in children. This review 
will explore the therapeutic potential of interrupting the enterohepatic 
circulation via pharmacologic blockade of IBAT and the associated im-
plications for treating cholestatic liver diseases and other disorders.
2  | OVERVIE W OF ALGS AND PFIC
ALGS and PFIC are genetic diseases that can present in paediatric 
patients as severe cholestasis and result from intrahepatic perturba-
tions.6,7 ALGS can be characterized by a reduction of intrahepatic bile 
ducts (in association with abnormalities in a number of non-liver organ 
systems such as heart defects, dysmorphic facial features, and vascu-
lar, vertebral and ocular anomalies),9,10 with clinical severity that ranges 
from biochemical liver abnormalities only to end-stage liver disease.10,11 
PFIC represents a group of disorders (with subtypes grouped based on 
the underlying genetic deficiency; eg ATP8B1-deficient PFIC, ABCB11-
deficient PFIC) in which disruption of bile homeostasis can eventually 
lead to cholestasis, cirrhosis, liver failure and death.12-14 Although dis-
tinctly different in many aspects, patients with ALGS and PFIC can share 
common clinical traits such as cholestasis, pruritus and an eventual 
need for liver transplantation.15,16 Table 1 provides additional details on 
the incidence, genetic basis, proposed mechanisms of disease, clinical 
presentation and disease progression of ALGS and PFIC.7,9-13,17-28
3  | BURDEN OF CHOLESTATIC LIVER 
DISE A SES
Previous studies have shown that patients with ALGS or PFIC have 
impaired quality of life, physical health and psychosocial function-
ing based on patient or parent proxy reports relative to healthy 
controls.29,30 Intractable pruritus has been identified as the most 
bothersome symptom of ALGS and PFIC; its marks can be visible as 
scratching-induced abrasions and scarring.9,18,31 Additional studies 
Key points
• Patients with the cholestatic liver diseases Alagille 
syndrome (ALGS) and progressive familial intrahepatic 
cholestasis (PFIC) have high disease burden and unmet 
medical needs.
• Currently, the only truly effective treatments for ALGS 
and PFIC are surgeries that disrupt the enterohepatic 
circulation of bile acids and liver transplantation.
• A number of potential treatment alternatives are in 
development to target mechanisms of cholestatic liver 
disease noninvasively, including ileal bile acid transport 
(IBAT) inhibitors.
• Phase 2 and 3 trial data suggest that IBAT inhibitors, 
which act by interrupting the enterohepatic circulation, 
may be safe and efficacious treatment options for ALGS 
and PFIC.
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have highlighted that severe pruritus is associated with functional 
impacts such as interference with sleep or mood disturbance.9,31,32
Liver transplantation is a common treatment for patients with 
ALGS or PFIC. The Global ALagille Alliance (GALA) study, which was 
described in a congress abstract reporting on a large cohort of pa-
tients with ALGS, found that 10-year native liver survival was no 
more than 70%.28 This is further illustrated in published data from 
293 patients with ALGS and cholestasis in the multicentre, prospec-
tive Childhood Liver Disease Research Network (ChiLDReN) study, in 
which estimated liver transplant-free survival was 24% at age 18.5.33 
The experience is similar for patients with PFIC. The 10-year native 
liver survival among patients with ATP8B1- and ABCB11-deficient 
PFIC, as reported by the NAtural course and Prognosis of PFIC and 
Effect of biliary Diversion (NAPPED) consortium, was 46%-51%.34 
Additional analyses from the NAPPED consortium found that the 
time of median native liver survival varied by underlying genotype in 
ABCB11-deficient PFIC; for example, certain missense mutations that 
produced BSEP with residual function were associated with a median 
native liver survival of 20.4 years, whereas mutations that completely 
disrupted the BSEP protein resulted in a median native liver survival of 
3.5 years.35 Healthcare costs in patients with PFIC and ALGS are likely 
considerable due to hospital visits and the need for long-term care.9,18
4  | CURRENT TRE ATMENT L ANDSC APE 
AND OPPORTUNITIES FOR THER APY
There are currently no approved drug treatments for either ALGS or 
PFIC. Medical treatment options are used supportively or for symp-
tomatic relief and may include off-label use of ursodeoxycholic acid 
(UDCA) to increase bile flow and reduce liver damage.36 Other medi-
cations are used to manage pruritus37 including cholestyramine, which 
sequesters bile acids in a resin complex for excretion38; rifampin, which 
activates the nuclear pregnane X receptor and is thought to increase 
the elimination of bilirubin and enhance enzymatic reactions that make 
bile acids more hydrophilic and less toxic39-41; naltrexone, an opioid an-
tagonist used to decrease opioid-mediated neurotransmission associ-
ated with pruritus and/or cholestasis42; or antihistamines. In addition, 
a high-calorie diet with vitamin/mineral supplementation (eg calcium, 
zinc and vitamins A, D, E and K) to provide nutritional support is fre-
quently prescribed.43 However, these approaches may not be entirely 
effective, and many patients either do not respond at all or require 
combination therapy.6,44
Surgical options for treating ALGS and PFIC include surgical bil-
iary diversion (SBD) and liver transplantation.6 SBD, such as partial 
external biliary diversion (PEBD), may be performed in patients with 
F I G U R E  1   Role of IBAT, bile acids and enterohepatic circulation in homeostasis and disease. A, Bile acids, synthesized in and secreted 
from the liver, travel to the small intestine where they aid in digestion and absorption of nutrients. Bile acids are reabsorbed from the 
terminal ileum by IBAT (95%) and return to the liver through the portal veins (indicated by the red line). This cycle is known as enterohepatic 
circulation. Bile acids not recovered in this process are replaced by nascent synthesis (5%), which is governed by inhibitory feedback from 
FGF19. The synthesis intermediate C4 is frequently used as a readout of bile acid synthesis. High bile acid levels in the ileum prompt FGF19 
signalling, which suppresses further bile acid production (indicated by a decrease in C4 levels). Typical bile acid concentrations in liver 
cells, the biliary and intestinal tracts and the portal circulation are given in milli- or micromolar quantities, as applicable.1 B, Pharmacologic 
inhibition of IBAT (the ileal bile acid transporter), a novel strategy being explored as treatment for Alagille syndrome and progressive familial 
intrahepatic cholestasis, prevents the recirculation of bile acids, shunting them away from the liver and towards faecal excretion instead, 
which is expected to reduce the overall size of the bile acid pool. C4 (7α-hydroxy-4-cholesten-3-one), bile acid precursor; FGF19, fibroblast 
growth factor 193
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severe pruritus that is not effectively managed with medications.16 
Liver transplantation is typically used for patients with end-stage liver 
disease, with hepatocellular carcinoma (increased risk for its develop-
ment in ABCB11 deficiency) or when other treatment options have 
been exhausted.45-47 While SBD and liver transplantation are viable 
treatment options for ALGS and PFIC, post-surgery issues such as the 
presence of a stoma (in the case of PEBD), the need for lifelong antire-
jection medication (in the case of transplant) or surgical complications 
may be practical limitations.15,48 Less invasive treatment options that 
can reduce the accumulation of bile acids in the liver and potentially 
relieve pruritus and cholestasis, limit the progression of liver disease 
and improve long-term prognosis would be valuable.
A number of alternative, nonsurgical therapies for cholestatic 
liver diseases, in general, are currently under investigation. These 
include modalities that target the FXR-FGF19 signalling axis (eg 
FXR agonists, FGF19 mimetics, obeticholic acid), cholehepatic 
drugs (eg norUDCA) and enterohepatic blockers (eg IBAT inhibi-
tors).49 Compounds that act through FXR or FGF19 are proposed to 
TA B L E  1   ALGS and PFIC: disease characteristics and pathophysiology
ALGS PFIC (group of disorders)
Inheritance Autosomal dominant Autosomal recessive
Incidence estimate 1/30 000 to 1/50 000 live births22 1/50 000 to 1/100 000 live births12
Genetics • Mutations or deletions in JAGGED1 or 
NOTCH2, with mutations in JAGGED1 
most common23,24
• Various genes affected that vary widely in normal function
a. All affect bile acid transport by hepatocytes, directly or 
indirectly19,26
• Genetic deficiencies that produce PFIC characterized by low-to-normal 
serum GGT levels include:
a. ATP8B1: the ATP8B1 protein regulates phospholipid distribution 
across the plasma membrane (PFIC subtype 1a )
b. ABCB11: ABCB11, a hepatocyte bile acid transporter that exports 
bile salts across the canalicular membrane (PFIC subtype 2a )
c. TJP2b : encodes TJP2 or zona-occludens 2, responsible for tight 
junction integrity between canalicular cells
d. NR1H4b : encodes FXR, the nuclear receptor that regulates 
expression of multiple genes related to bile transport and function, 
including BSEP
e. MYO5Bb : encodes myosin 5B, important for correct localization of 
transporters like BSEP
• Above-normal serum GGT levels are observed in ABCB4-deficient 
PFIC, which affects MDR3, a transporter of phosphatidylcholine, a 






• Abnormal development of intrahepatic 
bile ducts and bile duct paucity17,27
• Deficient bile salt transport (due to reduced activity of ABCB11 or 
aberrant functioning of FXR or myosin 5B)
• Aberrant composition of the canalicular membrane (due to ATP8B1 
deficiency), with secondary effects (eg reduced functionality of 
ABCB11)
Clinical presentation • ALGS is not fully penetrant (genetic 
confirmation necessary)10,11
• Cholestasis is common (typically 
presents within 3 mo of birth); usually 
diagnosed by age 19,10
• Other clinical characteristics may 
include elevated serum bile acids, 
pruritus, delayed growth, distinctive 
facial features, renal symptoms, 
xanthomas and vascular anomalies9,21
• Symptom onset in ATP8B1- and ABCB11-deficient patients typically 
occurs shortly after birth
a. Common symptoms include discoloured stool, hepatomegaly, 
pruritus and/or jaundice20,25
• Additional clinical characteristics12,13,20:
a. ATP8B1 deficiency: growth retardation and liver steatosis
b. ABCB11 deficiency: rapid development of end-stage liver disease
Disease progression • Estimated 10-y survival rate among 
patients with ALGS born between 
January 1997 and May 2019:93%
a. Native liver survival of this cohort: 
70%28
• In most cases, ATP8B1-, ABCB11- and ABCB4-deficient PFIC progress 
to liver failure before adulthood and are usually fatal if untreated7,12
• Mortality estimates range from 0% to 87%c 18
Note: Higher mortality estimates may reflect disease not treated by liver transplantation.
Abbreviations: ALGS, Alagille syndrome; BSEP, bile salt export pump; FXR, farnesoid X receptor; GGT, gamma-glutamyl transpeptidase; MDR3, 
multidrug resistance protein 3; PFIC, progressive familial intrahepatic cholestasis.
aHistorical nomenclature; current naming convention is based on genetic disruption. 
bOther subgroups of low-GGT PFIC are all very rare. 
cLower mortality rates may be driven by high rates of liver transplantation (range, 40%-100% among patients with ATP8B1 or ABCB11 deficiency). 
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stimulate bile acid transporter synthesis and the production of other 
gene products, with a cumulative effect of reducing intrahepatic bile 
acids level.50 Another promising compound is norUDCA, a derivative 
of UDCA that protects cholangiocytes from bile acid injury.50 These 
compounds have typically been evaluated in trials of cholestatic liver 
diseases in adults, and the benefits and risks to paediatric patients 
with ALGS and PFIC are unknown.
Potential therapies with specific applications for ALGS and 
PFIC include JAGGED1 small interfering RNAs and induced plu-
ripotent stem cells (reviewed in Feldman and Sokol,50 Morell and 
Strazzabosco,51 and Hansel et al52). In addition, there is a growing 
interest in IBAT inhibitors (currently in late-stage clinical develop-
ment for cholestatic liver diseases, including ALGS and PFIC) due to 
their specificity for IBAT in the intestine and their limited side-effect 
profile outside the gastrointestinal system. IBAT inhibitors are the 
focus of the rest of this review.
5  | INTERRUPTION OF THE 
ENTEROHEPATIC CIRCUL ATION A S A 
TRE ATMENT TARGET
Given that patients with ALGS and PFIC have intrahepatic accu-
mulations of bile acids that can damage tissues in the liver and spill 
over into systemic circulation, SBD procedures were developed to 
interrupt enterohepatic circulation and reduce the bile acid pool in 
these patients.8,15 SBD is often associated with reductions in serum 
bile acids and pruritus as well as improvements in sleep disturbance, 
quality of life, fibrosis and growth.53-55 In the case of PFIC, most 
of the currently available data on SBD are based on ATP8B1- and 
ABCB11-deficient patients.20,48,54,56-58
Findings from the NAPPED consortium showed that patients 
with ABCB11 deficiency who underwent SBD (n = 61) typically 
had reduced pruritus and serum bile acids relative to pre-surgery 
(pruritus was present in 97% of patients prior to surgery and in 
46% after SBD; mean serum bile acids decreased from 363 μmol/L 
initially to 48 μmol/L after SBD).35 Furthermore, a significant 
association was identified between lower post-SBD serum bile 
acids and long-term native liver survival: patients whose serum 
bile acids were <102 μmol/L after SBD survived up to 15 years 
with their native liver intact vs patients whose serum bile acids 
were ≥102 μmol/L, for whom less than half had this outcome.35 
Similarly, in a systematic review and meta-analysis evaluating 
studies with pre- and post-PEBD liver biochemistry values, pa-
tients with PFIC with reduced serum bile acids post-PEBD were 
more likely to have favourable clinical responses (ie, improved pru-
ritus, decreased need for liver transplant).59 Thus, the reduction 
in bile acids and improvement in clinical outcomes observed with 
SBD provide a strong rationale that disrupting enterohepatic cir-
culation holds promise for treating patients with cholestatic liver 
disease. Data from the NAPPED consortium also indicated that 
patient genotype, at least in the case of ABCB11-deficient PFIC 
for which data are available, may influence long-term outcomes 
following SBD; these data hint at a possibility for personalized 
medicine approaches in the future.35
Inhibition of IBAT represents a pharmacologic approach for 
achieving the same ends as SBD: that is, interruption of the entero-
hepatic circulation of bile acids. IBAT is an integral brush border 
membrane glycoprotein that co-transports sodium and bile acids and 
is a major regulator of the bile acid pool size in animals and humans.60 
IBAT inhibition prevents the intestinal reabsorption of bile acids to 
reduce bile acids in the liver and would be a nonsurgical alternative 
to SBD. Genetic ablation of IBAT in mice demonstrated that loss of 
IBAT function and the resulting redirection of bile acids to the colon 
cannot fully compensate for the increase in bile acid synthesis61; 
based on this premise, selective IBAT inhibition is thought to produce 
a net reduction in the hepatic exposure to bile acids (Figure 1B).3
One piece of evidence that IBAT inhibition could provide benefits 
similar to SBD is provided by a case report of a patient with ABCB11 
deficiency.62 This patient was treated with the IBAT inhibitor ode-
vixibat in a phase 2 clinical trial63 and experienced improvements 
in serum bile acids, pruritus and sleep. When the trial ended, the 
patient's symptoms returned. The patient subsequently underwent 
PEBD, which resulted in reductions in pruritus and serum bile acids 
and improvements in sleep similar to those achieved with prior IBAT 
inhibitor treatment, suggesting that in this patient, IBAT inhibition 
was as effective as PEBD for treating cholestasis.62
6  | IBAT INHIBITORS IN DE VELOPMENT
Key preclinical and clinical data for 5 IBAT inhibitors in development 
are summarized in Table 2.63-81 All are selective, reversible small 
molecule inhibitors of IBAT, administered orally once or twice daily. 
Overall, study data supported the anticipated effects of IBAT inhibi-
tion, that is, decreased hepatic and circulating bile acid levels accom-
panied by increased fecal bile acid excretion.82-86
IBAT inhibitors are currently in development for a range of target 
indications across both paediatric (eg PFIC, ALGS and others) and 
adult (eg PBC, PSC, others) populations. In cholestatic liver diseases, 
preventing the return of bile acids to the liver via IBAT inhibition 
may relieve the inflammatory and fibrotic pressures driving tissue 
damage such that cholestasis and liver function may improve.3,69 
Because IBAT inhibition results in more bile acids redirected to the 
colon (which stimulates colonic motility), IBAT inhibitors are also 
being investigated to treat constipation.87 Finally, because bile salts 
can act as signalling molecules via their interactions with nuclear 
receptors and downstream targets including genes involved in lipid 
and glucose metabolism, they may also be potentially useful in the 
treatment of metabolic disorders such as type 2 diabetes mellitus or 
nonalcoholic steatohepatitis (NASH).88
Two IBAT inhibitors, maralixibat and odevixibat, have been 
evaluated in phase 2 and phase 3 clinical trials of paediatric patients 
with ALGS and PFIC; however, much of the available clinical data 
are from results thus far only presented at scientific congresses, 
with 1 exception for which data from a peer-reviewed publication 
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TA B L E  2   IBAT inhibitors currently in development
IBAT inhibitor
Target 
indication(s) Key preclinical findings Key clinical findings Current status





ALGS; PFIC; BA 
(planned)
• A close analogue, SC-435, 
reduced bile acids and 
cholestatic liver injury and 
improved expression of 
proinflammatory and fibrotic 
markers in Mdr2−/− mice81
• Reduced serum bile acids and 
liver tissue damage in rats 
with partial bile duct ligation 
(cholestasis model)64
• The 2 highest doses did not 
reduce pruritus vs placebo 
(prespecified primary analysis), 
although improved pruritus 
was observed with the 2 lowest 
doses in a phase 2 trial (ITCH) for 
paediatric patients with ALGS 
(study duration, 17 wk)65
• Serum bile acids were reduced 
and pruritus was improved in an 
interim analysis of an open-
label phase 2 study (ICONIC) in 
paediatric patients with ALGS 
(study duration, 100 wk); the 
most frequently reported AEs 
were diarrhoea, abdominal pain, 
vomiting and URTI66
• Reduced serum bile acids and 
pruritus at week 48 in an open-
label phase 2 study (INDIGO) in 
children aged 1-13 y with PFIC; 
treatment response up to week 
72 was associated with improved 
growth67,68
• Orphan drug 
designation by FDA 
and EMA for ALGS, 
PFIC, PBC and PSC
• FDA breakthrough 
therapy designation 
for PFIC-2 and ALGS












Odevixibat (A4250) PFIC; ALGS; BA • Negative cytotoxicity; no 
effect on CNS, renal, GI tract, 
respiratory or CV parameters; 
well tolerated with primarily GI 
findings; good safety margins for 
projected clinical doses (data on 
file, Albireo Pharma, Inc)
• Reduced bile acids and 
cholestatic liver injury and 
improved expression of 
proinflammatory and fibrotic 
markers in Mdr2−/− mice69
• Improved bile acids, pruritus 
and sleep in a phase 2, dose-
escalation, open-label study 
(study duration, 8-10 wk) that 
enrolled patients aged 1-18 y 
with pruritus and PFIC, ALGS, BA 
or other causes of intrahepatic 
cholestasis; the most common 
AEs were ear infection and 
pyrexia, which were deemed 
unrelated to treatment63,70,71
• Orphan drug 
designation by FDA 
and EMA for ALGS, 
PFIC, BA and PBC
• FDA fast track 
designation for PFIC in 
2018
• Phase 3 study in 
PFIC (PEDFIC-1 
[NCT03566238]) 




• Phase 3 study 
in BA (BOLD 
[NCT04336722]) 
initiated in 202098






• Improved constipation 
symptoms in dogs72
• Demonstrated efficacy and safety 
for chronic idiopathic constipation 
in phase 2 and 3 studies in the US 
and Japan for up to 52 wk73,74
• Produced favourable metabolic 
effects vs placebo (eg decreased 
LDL cholesterol, increased GLP-1) 
in patients with dyslipidaemia 
or chronic constipation 
(study durations, 6 and 2 wk 
respectively)75,92
• Received approval 
in Japan in 2018 
for treatment of 
constipation
• A phase 2 trial 
for NAFLD or 
NASH is underway 
(NCT04006145)
(Continues)
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are available.65 Maralixibat has been evaluated for ALGS in 2 
phase 2 trials (ITCH65 and IMAGO [some study results were in-
cluded with ITCH study findings]) and in three additional long-term 
phase 2 trials that are ongoing (ICONIC66,89 and IMAGINE-I90 and 
–II, extensions of the IMAGO trial). In the ITCH trial, the group of 
patients with ALGS treated with the two highest doses of mara-
lixibat did not show a difference from placebo on a measure of 
pruritus (assessed via the observer-rated Itch Reported Outcome 
scale).65,91 However, among all patients treated with maralixibat (3 
dose groups combined), a greater proportion achieved a 1-point 
pruritus score reduction than those who received placebo (68% 
vs 25%). The change from baseline in total serum bile acids for any 
maralixibat group was similar to the change observed with placebo. 
Gastrointestinal side effects were reported by approximately half 
of all patients treated with maralixibat, but none were severe. 
Additionally, maralixibat is being evaluated for PFIC in 2 long-term 
studies: the phase 2 INDIGO67 study and the phase 3 MARCH-
PFIC trial.
Odevixibat was evaluated as treatment for paediatric cholestatic 
liver diseases, including ALGS and PFIC, in a phase 2 study.63 Key 
findings from this study include reductions in serum bile acids from 
baseline (with some patients experiencing up to a 98% reduction) 
and improvements in patient-recorded pruritic and sleep distur-
bance symptoms (pruritus was assessed using 3 scales).63 Overall, 
7/24 patients reported any gastrointestinal adverse event, and all 
but 1 were mild or moderate in severity. A phase 3 study and its long-
term extension study evaluating odevixibat in patients with PFIC are 
underway (PEDFIC-1 and PEDFIC-2, respectively; PEDFIC-2 also in-
cludes a cohort of patients with other types of PFIC).
IBAT inhibitors are also in clinical development for other choles-
tatic liver diseases and indications, for which phase 2 and 3 data are 
summarized below. For the studies described below, some data were 
available from published abstracts only, but the majority of data 
were available in peer-reviewed publications.73-75,77,78,92-95
Maralixibat has been evaluated in phase 2 trials for cholestatic 
liver disease in adults (PBC,94 PSC96), and a trial investigating mara-
lixibat for biliary atresia is planned for 2020.97 The phase 2 study of 
odevixibat described above also evaluated paediatric patients with 
other types of cholestatic liver disease, including those with di-
agnoses of biliary atresia, multidrug resistance protein 3-deficient 
PFIC and other causes of intrahepatic cholestasis.63,70,71 A trial 
investigating odevixibat for biliary atresia (BOLD; NCT04336722) 
started in 2020.98 Furthermore, odevixibat was evaluated as treat-
ment for adults with PBC.95 Elobixibat is approved in Japan for 
the treatment of chronic constipation (supported by clinical data 
from a number of phase 273,92 and phase 374 studies), and is cur-
rently being explored in a phase 2 study of patients with either 
nonalcoholic fatty liver disease or NASH (NCT04006145); phase 
2 studies indicated metabolic effects of elobixibat.75 The IBAT 
inhibitor linerixibat demonstrated efficacy in reducing pruritus 
severity in adults with PBC.77 In another phase 2 study, pruritus 
in patients with PBC was associated with elevated serum bile 
acids and autotaxin levels, and treatment with linerixibat reduced 
serum bile acids.93 Linerixibat is currently being investigated in 
IBAT inhibitor
Target 







• Lowered glucose levels in a 
diabetic rat model76
• Reduced serum bile acids and 
pruritus relative to placebo in a 
phase 2 crossover trial of PBC in 
adults (study duration, 8-14 wk); 
well tolerated, with diarrhoea as 
the most common AE77
• Reduced glucose and lipid 
levels vs placebo in adults with 
type 2 diabetes in 2 studies 
(study durations, 6-8 and 5 wk 
respectively); high incidence of 
GI-related AEs of mild or moderate 
severity78
• A phase 2 study for 
PBC is currently 
underway 
(NCT02966834)
Volixibat (SHP626) NASH; ICP; 
PSC
• Lowered cholesterol and insulin 
levels, reduced hepatocyte 
hypertrophy and increased total 
bile acids in faeces in a NASH 
mouse model79
• Phase 2 trial in NASH patients 
terminated by sponsor in 2018 
after no difference found vs 
placebo on MRI proton density fat 
fraction, serum ALT levels or liver 
histology at 24 wk80
• FDA fast track 
designation for NASH 
in 2016
• Studies for ICP and 
PSC are planned for 
2020 (trials not yet 
registered)
Abbreviations: AE, adverse event; ALGS, Alagille syndrome; ALT, alanine aminotransferase; BA, biliary atresia; CNS, central nervous system; 
CV, cardiovascular; EMA, European Medicines Agency; FDA, United States Food and Drug Administration; GI, gastrointestinal; GLP-1, glucose-
dependent insulinotropic peptide; IBAT, ileal bile acid transporter; ICP, intrahepatic cholestasis of pregnancy; LDL, low density lipoprotein; MRI, 
magnetic resonance imaging; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis; PFIC, 
progressive familial intrahepatic cholestasis; PSC, primary sclerosing cholangitis; URTI, upper respiratory tract infection.
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a phase 2 dose-response trial of adults with PBC and pruritus 
(NCT02966834), and previously was evaluated in a phase 2 trial 
for type 2 diabetes.78 The IBAT inhibitor volixibat did not meet the 
primary efficacy endpoint in a phase 2 trial for the treatment of 
NASH.80 Finally, 2 trials to investigate volixibat in PSC and intra-
hepatic cholestasis of pregnancy are planned to initiate in 2020. 
Because bile-modulating therapies including IBAT inhibitors are 
being explored for the treatment of PSC in adults,99,100 IBAT inhi-
bition may also be a potential therapeutic option in children with 
PSC; however, clinical studies are needed to determine efficacy 
and safety in this population.
7  | CONCLUSIONS
ALGS and PFIC are rare, inherited childhood disorders that manifest 
with cholestasis and pruritus as well as progressive, life-threatening 
liver disease. Limited treatments are available, and there are cur-
rently no approved pharmacologic therapies. Preclinical and clinical 
data support IBAT inhibitors as noninvasive options to interrupt the 
enterohepatic circulation to treat cholestatic liver diseases and other 
disorders. These orally administered, selective and reversible com-
pounds decrease enteric bile acid reuptake with minimal systemic 
exposure. They may play an important role in reducing the symptoms 
of ALGS and PFIC by pharmacologically interrupting the enterohe-
patic circulation of bile acids, thus reducing bile acid accumulation in 
the liver and reducing the potential for hepatobiliary injury.
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